- ₹10 crore of the proceeds from the fresh issue will be used to repay or prepay certain borrowings availed by the company.
- The current growth of the company has been aided by the geographical advantage of being located in Noida, Greater Noida and Noida Extension
- The equity shares are being made available for purchase through the red herring prospectus of the company, dated July 18, 2023, which has been filed with the Registrar of Companies.
The anchor investor bidding date is scheduled for Tuesday, July 25, 2023. The subscription for the offer will open on Wednesday, July 26, 2023, and conclude on Friday, July 28, 2023.
The company has fixed the price band for its equity shares at ₹285 to ₹300 per share, allowing bids for a minimum of 50 equity shares and in multiples of 50 thereafter.
The net proceeds from the fresh issue will be utilized as follows: firstly, up to ₹10 crore will be used to repay or prepay certain borrowings availed by the company; secondly, up to ₹14.5 crore will go towards repaying or prepaying borrowings of its subsidiaries, AKS Medical and Research Centre and Ramraja Multispeciality Hospital and Trauma Centre, and thirdly, ₹2.56 crore will be allocated to fund the
Also the company's subsidiaries, AKS and Ramraja, will receive up to ₹10.69 crore to support their respective hospital's capital expenditure expenses, and ₹6.5 crore is intended for funding inorganic growth initiatives through acquisitions and other strategic endeavors; and finally, the remaining balance will be utilised for general corporate purposes.
The offer for sale consists of three categories of equity shares being offered by the promoter group sellings shareholders: up to 3,743,000 equity shares by Vimla Tyagi, up to 2,021,200 equity shares by Prem Narayan Tyagi, and up to 787,490 equity shares by Neena Tyagi.
According to analysts at Axis Capital, the current growth of the company has been aided by the geographical advantage of being located in Noida, Greater Noida and Noida Extension. The Gautam Buddh Nagar district, the area in which their existing hospitals are situated, has witnessed strong economic growth in the last few years. These areas have developed rapidly in recent years on account of the growing real estate, economic development in these regions and increased purchasing power.
Further, employment and capital invested in industries in these regions has been growing at a good rate, indicating potential for growth and economic activity. Being located in these regions allows them to serve patients from UP, Delhi, Haryana, Uttarakhand and other states as well. Their recent acquisition of the Jhansi-Orchha hospital is aimed at further expanding into new geographies and growing their presence in the regional healthcare market.
However, as mentioned in the Red Herring Prospectus, this is also a potential risk. The company's operations are primarily concentrated in the Delhi NCR region. It heavily relies on certain specialties for a significant portion of its revenues. The financial performance of these hospitals and the earnings from its key specialties play a crucial role in shaping the overall business outcomes, financial condition, results of operations, and cash flows.
Their ability to attract, retain, and train healthcare professionals, and operational, reputational, medical and legal claims, regulatory actions or other liabilities that could adversely affect their reputation and prospect have been identified among other risks.
The equity shares are being made available for purchase through the red herring prospectus of the company, dated July 18, 2023, which has been filed with the Registrar of Companies, National Capital Territory of Delhi and Haryana. The plan is to have these shares listed on recognised stock exchanges, namely BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE"). BSE has been designated as the specific stock exchange for the Offer.